Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
Identifieur interne : 000526 ( PubMed/Curation ); précédent : 000525; suivant : 000527Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
Auteurs : Jianhui Nie [République populaire de Chine] ; Qianqian Li [République populaire de Chine] ; Jiajing Wu [République populaire de Chine] ; Chenyan Zhao [République populaire de Chine] ; Huan Hao [République populaire de Chine] ; Huan Liu [République populaire de Chine] ; Li Zhang [République populaire de Chine] ; Lingling Nie [République populaire de Chine] ; Haiyang Qin [République populaire de Chine] ; Meng Wang [République populaire de Chine] ; Qiong Lu [République populaire de Chine] ; Xiaoyu Li [République populaire de Chine] ; Qiyu Sun [République populaire de Chine] ; Junkai Liu [République populaire de Chine] ; Changfa Fan [République populaire de Chine] ; Weijin Huang [République populaire de Chine] ; Miao Xu [République populaire de Chine] ; Youchun Wang [République populaire de Chine]Source :
- Emerging microbes & infections [ 2222-1751 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (immunologie), Glycoprotéines membranaires (immunologie), Humains, Immunisation passive, Infections à coronavirus (), Infections à coronavirus (immunologie), Lignée cellulaire, Limite de détection, Plasmides, Pneumopathie virale (immunologie), Protéines de l'enveloppe virale (immunologie), Pénétration virale, Reproductibilité des résultats, Sensibilité et spécificité, Souris, Sérums immuns (immunologie), Tests de neutralisation, Virus de la stomatite vésiculeuse de type Indiana (génétique).
- MESH :
- génétique : Glycoprotéine de spicule des coronavirus, Virus de la stomatite vésiculeuse de type Indiana.
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Infections à coronavirus, Pneumopathie virale, Protéines de l'enveloppe virale, Sérums immuns.
- Animaux, Humains, Immunisation passive, Infections à coronavirus, Lignée cellulaire, Limite de détection, Plasmides, Pénétration virale, Reproductibilité des résultats, Sensibilité et spécificité, Souris, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Betacoronavirus (immunology), Cell Line, Coronavirus Infections (immunology), Coronavirus Infections (therapy), Humans, Immune Sera (immunology), Immunization, Passive, Limit of Detection, Membrane Glycoproteins (immunology), Mice, Neutralization Tests, Plasmids, Pneumonia, Viral (immunology), Reproducibility of Results, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Vesicular stomatitis Indiana virus (genetics), Viral Envelope Proteins (immunology), Virus Internalization.
- MESH :
- chemical , genetics : Spike Glycoprotein, Coronavirus.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Immune Sera, Membrane Glycoproteins, Spike Glycoprotein, Coronavirus, Viral Envelope Proteins.
- genetics : Vesicular stomatitis Indiana virus.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections.
- Animals, Cell Line, Humans, Immunization, Passive, Limit of Detection, Mice, Neutralization Tests, Plasmids, Reproducibility of Results, Sensitivity and Specificity, Virus Internalization.
Abstract
Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.
DOI: 10.1080/22221751.2020.1743767
PubMed: 32207377
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000526
Links to Exploration step
pubmed:32207377Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.</title><author><name sortKey="Nie, Jianhui" sort="Nie, Jianhui" uniqKey="Nie J" first="Jianhui" last="Nie">Jianhui Nie</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Li, Qianqian" sort="Li, Qianqian" uniqKey="Li Q" first="Qianqian" last="Li">Qianqian Li</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Jiajing" sort="Wu, Jiajing" uniqKey="Wu J" first="Jiajing" last="Wu">Jiajing Wu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhao, Chenyan" sort="Zhao, Chenyan" uniqKey="Zhao C" first="Chenyan" last="Zhao">Chenyan Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Hao, Huan" sort="Hao, Huan" uniqKey="Hao H" first="Huan" last="Hao">Huan Hao</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Huan" sort="Liu, Huan" uniqKey="Liu H" first="Huan" last="Liu">Huan Liu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Nie, Lingling" sort="Nie, Lingling" uniqKey="Nie L" first="Lingling" last="Nie">Lingling Nie</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Qin, Haiyang" sort="Qin, Haiyang" uniqKey="Qin H" first="Haiyang" last="Qin">Haiyang Qin</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Meng" sort="Wang, Meng" uniqKey="Wang M" first="Meng" last="Wang">Meng Wang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Qiong" sort="Lu, Qiong" uniqKey="Lu Q" first="Qiong" last="Lu">Qiong Lu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Li, Xiaoyu" sort="Li, Xiaoyu" uniqKey="Li X" first="Xiaoyu" last="Li">Xiaoyu Li</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Qiyu" sort="Sun, Qiyu" uniqKey="Sun Q" first="Qiyu" last="Sun">Qiyu Sun</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Junkai" sort="Liu, Junkai" uniqKey="Liu J" first="Junkai" last="Liu">Junkai Liu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Fan, Changfa" sort="Fan, Changfa" uniqKey="Fan C" first="Changfa" last="Fan">Changfa Fan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Weijin" sort="Huang, Weijin" uniqKey="Huang W" first="Weijin" last="Huang">Weijin Huang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Xu, Miao" sort="Xu, Miao" uniqKey="Xu M" first="Miao" last="Xu">Miao Xu</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Youchun" sort="Wang, Youchun" uniqKey="Wang Y" first="Youchun" last="Wang">Youchun Wang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32207377</idno><idno type="pmid">32207377</idno><idno type="doi">10.1080/22221751.2020.1743767</idno><idno type="wicri:Area/PubMed/Corpus">000526</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000526</idno><idno type="wicri:Area/PubMed/Curation">000526</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.</title><author><name sortKey="Nie, Jianhui" sort="Nie, Jianhui" uniqKey="Nie J" first="Jianhui" last="Nie">Jianhui Nie</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Li, Qianqian" sort="Li, Qianqian" uniqKey="Li Q" first="Qianqian" last="Li">Qianqian Li</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Jiajing" sort="Wu, Jiajing" uniqKey="Wu J" first="Jiajing" last="Wu">Jiajing Wu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhao, Chenyan" sort="Zhao, Chenyan" uniqKey="Zhao C" first="Chenyan" last="Zhao">Chenyan Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Hao, Huan" sort="Hao, Huan" uniqKey="Hao H" first="Huan" last="Hao">Huan Hao</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Huan" sort="Liu, Huan" uniqKey="Liu H" first="Huan" last="Liu">Huan Liu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Nie, Lingling" sort="Nie, Lingling" uniqKey="Nie L" first="Lingling" last="Nie">Lingling Nie</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Qin, Haiyang" sort="Qin, Haiyang" uniqKey="Qin H" first="Haiyang" last="Qin">Haiyang Qin</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Meng" sort="Wang, Meng" uniqKey="Wang M" first="Meng" last="Wang">Meng Wang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Qiong" sort="Lu, Qiong" uniqKey="Lu Q" first="Qiong" last="Lu">Qiong Lu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Li, Xiaoyu" sort="Li, Xiaoyu" uniqKey="Li X" first="Xiaoyu" last="Li">Xiaoyu Li</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Qiyu" sort="Sun, Qiyu" uniqKey="Sun Q" first="Qiyu" last="Sun">Qiyu Sun</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Junkai" sort="Liu, Junkai" uniqKey="Liu J" first="Junkai" last="Liu">Junkai Liu</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Fan, Changfa" sort="Fan, Changfa" uniqKey="Fan C" first="Changfa" last="Fan">Changfa Fan</name><affiliation wicri:level="1"><nlm:affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Huang, Weijin" sort="Huang, Weijin" uniqKey="Huang W" first="Weijin" last="Huang">Weijin Huang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Xu, Miao" sort="Xu, Miao" uniqKey="Xu M" first="Miao" last="Xu">Miao Xu</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Youchun" sort="Wang, Youchun" uniqKey="Wang Y" first="Youchun" last="Wang">Youchun Wang</name><affiliation wicri:level="1"><nlm:affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing</wicri:regionArea></affiliation></author></analytic><series><title level="j">Emerging microbes & infections</title><idno type="eISSN">2222-1751</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Viral (immunology)</term><term>Betacoronavirus (immunology)</term><term>Cell Line</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (therapy)</term><term>Humans</term><term>Immune Sera (immunology)</term><term>Immunization, Passive</term><term>Limit of Detection</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Neutralization Tests</term><term>Plasmids</term><term>Pneumonia, Viral (immunology)</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Vesicular stomatitis Indiana virus (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Virus Internalization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps neutralisants (immunologie)</term><term>Glycoprotéine de spicule des coronavirus (génétique)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Immunisation passive</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (immunologie)</term><term>Lignée cellulaire</term><term>Limite de détection</term><term>Plasmides</term><term>Pneumopathie virale (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Pénétration virale</term><term>Reproductibilité des résultats</term><term>Sensibilité et spécificité</term><term>Souris</term><term>Sérums immuns (immunologie)</term><term>Tests de neutralisation</term><term>Virus de la stomatite vésiculeuse de type Indiana (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Immune Sera</term><term>Membrane Glycoproteins</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Vesicular stomatitis Indiana virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Virus de la stomatite vésiculeuse de type Indiana</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Protéines de l'enveloppe virale</term><term>Sérums immuns</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Humans</term><term>Immunization, Passive</term><term>Limit of Detection</term><term>Mice</term><term>Neutralization Tests</term><term>Plasmids</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Immunisation passive</term><term>Infections à coronavirus</term><term>Lignée cellulaire</term><term>Limite de détection</term><term>Plasmides</term><term>Pénétration virale</term><term>Reproductibilité des résultats</term><term>Sensibilité et spécificité</term><term>Souris</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32207377</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes & infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.</ArticleTitle><Pagination><MedlinePgn>680-686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2020.1743767</ELocationID><Abstract><AbstractText>Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Jianhui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiajing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chenyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Haiyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Qiyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Junkai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Changfa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Youchun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C028391">G protein, vesicular stomatitis virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike glycoprotein, COVID-19 virus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="Y">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014721" MajorTopicYN="N">Vesicular stomatitis Indiana virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">neutralization assay</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">pseudovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32207377</ArticleId><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Mar 26;382(13):1199-1207</Citation><ArticleIdList><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Biotechnol. 2018 Jun;51:64-69</Citation><ArticleIdList><ArticleId IdType="pubmed">29223005</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Sep 12;35(38):5172-5178</Citation><ArticleIdList><ArticleId IdType="pubmed">28797730</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2017 Feb 20;7:42769</Citation><ArticleIdList><ArticleId IdType="pubmed">28218278</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 2016;96:245-286</Citation><ArticleIdList><ArticleId IdType="pubmed">27712626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2010 Nov;169(2):365-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20709108</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16022774</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2019 Oct 8;37(43):6526-6534</Citation><ArticleIdList><ArticleId IdType="pubmed">31500967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rev Med Virol. 2018 Jan;28(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">29218769</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):221-236</Citation><ArticleIdList><ArticleId IdType="pubmed">31987001</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2018 Jan 2;14(1):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">28933644</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 30;7:45552</Citation><ArticleIdList><ArticleId IdType="pubmed">28358050</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2020 Jan 30;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31999307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Nov 7;35(47):6387-6394</Citation><ArticleIdList><ArticleId IdType="pubmed">29031692</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Vaccines. 2009 Jul;8(7):887-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19538115</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2019;15(10):2286-2294</Citation><ArticleIdList><ArticleId IdType="pubmed">31170027</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):32-41</Citation><ArticleIdList><ArticleId IdType="pubmed">31859609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2017 Aug 3;13(8):1811-1817</Citation><ArticleIdList><ArticleId IdType="pubmed">28481728</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2020 Apr;92(4):418-423</Citation><ArticleIdList><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2018 Aug 23;10(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">30142928</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Host Microbe. 2020 Mar 11;27(3):325-328</Citation><ArticleIdList><ArticleId IdType="pubmed">32035028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2020 Feb;91:264-266</Citation><ArticleIdList><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2019;8(1):272-281</Citation><ArticleIdList><ArticleId IdType="pubmed">30866781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000526 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000526 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32207377
|texte= Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32207377" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |